A Phase I, Multi-centre, Open-label, Uncontrolled, Non-randomised Study to Evaluate the Systemic Exposure and Safety of Ingenol Mebutate When Applied to Full Face, Balding Scalp or an Area of Approximately 250 cm2 on the Arm in Subjects With Actinic Keratosis

Trial Profile

A Phase I, Multi-centre, Open-label, Uncontrolled, Non-randomised Study to Evaluate the Systemic Exposure and Safety of Ingenol Mebutate When Applied to Full Face, Balding Scalp or an Area of Approximately 250 cm2 on the Arm in Subjects With Actinic Keratosis

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2015

At a glance

  • Drugs Ingenol mebutate (Primary)
  • Indications Actinic keratosis
  • Focus Pharmacokinetics
  • Sponsors LEO Pharma
  • Most Recent Events

    • 08 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 01 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top